Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0007408
UniProt IDP20226
Primary gene name(s)TBP
Synonym gene name(s)GTF2D1, TF2D, TFIID
Protein nameTATA-box-binding protein
Protein functionGeneral transcription factor that functions at the core of the DNA-binding multiprotein factor TFIID, PubMed:2374612, PubMed:2363050, PubMed:2194289, PubMed:9836642, PubMed:27193682. Binding of TFIID to the TATA box is the initial transcriptional step of the pre-initiation complex, PIC, playing a role in the activation of eukaryotic genes transcribed by RNA polymerase II, PubMed:2374612, PubMed:2363050, PubMed:2194289, PubMed:9836642, PubMed:27193682. Component of a BRF2-containing transcription factor complex that regulates transcription mediated by RNA polymerase III, PubMed:26638071. Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC, pre-initiation complex during RNA polymerase I-dependent transcription, PubMed:15970593. The rate of PIC formation probably is primarily dependent on the rate of association of SL1 with the rDNA promoter. SL1 is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA. {ECO:0000269|PubMed:15970593, ECO:0000269|PubMed:2194289, ECO:0000269|PubMed:2363050, ECO:0000269|PubMed:2374612, ECO:0000269|PubMed:26638071, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:9836642, ECO:0000305}.
Subcellular locationNucleus {ECO:0000269|PubMed:27007846}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P20226
Gene Ontology
(Biological Process)
Complete annatation
positive regulation of gene expression, epigenetic [GO:0045815];
positive regulation of transcription, DNA-templated [GO:0045893];
regulation of signal transduction by p53 class mediator [GO:1901796];
snRNA transcription from RNA polymerase II promoter [GO:0042795];
spermatogenesis [GO:0007283];
termination of RNA polymerase I transcription [GO:0006363];
transcription elongation from RNA polymerase II promoter [GO:0006368];
transcription elongation from RNA polymerase I promoter [GO:0006362];
transcription from RNA polymerase III promoter [GO:0006383];
transcription from RNA polymerase II promoter [GO:0006366];
transcription initiation from RNA polymerase II promoter [GO:0006367];
transcription initiation from RNA polymerase I promoter [GO:0006361];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
enzyme binding [GO:0019899];
repressing transcription factor binding [GO:0070491];
RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978];
RNA polymerase II core promoter sequence-specific DNA binding [GO:0000979];
transcription factor activity, sequence-specific DNA binding [GO:0003700];
transcription factor binding [GO:0008134];
transcription regulatory region DNA binding [GO:0044212]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
female pronucleus [GO:0001939];
male pronucleus [GO:0001940];
nuclear euchromatin [GO:0005719];
nucleoplasm [GO:0005654];
transcription factor TFIIA complex [GO:0005672];
transcription factor TFIID complex [GO:0005669]
Protein-protein interaction112771
Phylogenetic treeP20226
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.6312629146927770.05575822727164460.109425521020603
AZA vs. DISU-0.01690648356767250.9472360981236060.996198528027442
AZA vs. IL7-0.09532213291792760.6265376429072130.999311006273513
AZA vs. SAHA-0.02454502222142240.92077782076040.982071981797342
DISU vs. CD3-0.6615322641345930.07055865943605280.14192017298911
DISU vs. IL7-0.08740997091476140.7310901248007360.932983648383965
DISU vs. SAHA-0.005552201344684870.9849289100018690.997928641020292
DMSO vs. AZA-0.06047963425871810.7248534314529741
DMSO vs. CD3-0.7032781854450020.02926424293677420.0615476504038117
DMSO vs. DISU-0.04529381891441870.854134450517440.983556672216537
DMSO vs. IL7-0.02758364884014670.8804572391149330.973741241064909
DMSO vs. SAHA0.02998253909699430.8999624813491350.975637211233665
HIV vs. Mock in Activation0.05829187250519330.9254674279567840.999983755607037
HIV vs. Mock in Latency-0.009081846209628490.9569554808581240.999834320637052
IL7 vs. CD3-0.7198203337285550.02641130223899310.0654658047440131
SAHA vs. CD3-0.6797248259841170.05602981695548510.108852564331463
SAHA vs. IL70.06801780437417730.7824200285798630.904671282565993
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 1.36879 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.995 1.016 0.941 0.894 1.012
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1C9B X-ray 2.6Å B/F/J/N/R=159-337.
1CDW X-ray 1.9Å A=159-337.
1JFI X-ray 2.6Å C=159-339.
1NVP X-ray 2.1Å A=159-339.
1TGH X-ray 2.9Å A=156-339.
4ROC X-ray 1.9Å B=159-339.
4ROD X-ray 2.7Å B=159-339.
4ROE X-ray 2.2Å B=159-339.
5FUR EM 8.5Å A=1-339.
5IY6 EM 7.2Å P=1-339.
5IY7 EM 8.6Å P=1-339.
5IY8 EM 7.9Å P=1-339.
5IY9 EM 6.3Å P=1-339.
5IYA EM 5.4Å P=1-339.
5IYB EM 3.9Å P=1-339.
5IYC EM 3.9Å P=1-339.
5IYD EM 3.9Å P=1-339.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa03022 Basal transcription factors - Homo sapiens (human)
hsa05016 Huntington's disease - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
Menu